Trial Profile
To Evaluate the safety and efficacy of Daclatasvir plus Asunaprevir in hepatitis C patients with pre-existing resistance associated variants (RAVs) for genotype-1 with previous pegIFN+ribavirin failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Aug 2015
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 13 Aug 2015 New trial record